--- title: "Carlsmed (NASDAQ:CARL) Price Target Lowered to $17.00 at The Goldman Sachs Group" type: "News" locale: "en" url: "https://longbridge.com/en/news/282235684.md" description: "The Goldman Sachs Group has lowered its price target for Carlsmed (NASDAQ:CARL) from $19.00 to $17.00 while maintaining a \"buy\" rating. This new target suggests a potential upside of 75.15% from the previous close. Other analysts have mixed ratings, with three giving a \"buy,\" one a \"hold,\" and one a \"sell.\" Carlsmed's stock recently traded down 2.8% to $9.71, with a market cap of $259.44 million. The company reported a quarterly loss of ($0.32) per share, beating estimates, and had revenue of $15.16 million." datetime: "2026-04-09T18:06:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282235684.md) - [en](https://longbridge.com/en/news/282235684.md) - [zh-HK](https://longbridge.com/zh-HK/news/282235684.md) generator: "portal-rs" --- # Carlsmed (NASDAQ:CARL) Price Target Lowered to $17.00 at The Goldman Sachs Group Carlsmed (NASDAQ:CARL - Get Free Report) had its target price lowered by equities researchers at The Goldman Sachs Group from $19.00 to $17.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. The Goldman Sachs Group's price target would suggest a potential upside of 75.15% from the company's previous close. A number of other research firms also recently weighed in on CARL. BTIG Research reaffirmed a "buy" rating and set a $24.00 price target on shares of Carlsmed in a research report on Monday, December 15th. Weiss Ratings reaffirmed a "sell (e-)" rating on shares of Carlsmed in a research report on Monday, December 22nd. Zacks Research raised Carlsmed from a "strong sell" rating to a "hold" rating in a research report on Thursday, March 26th. Finally, Wall Street Zen raised Carlsmed from a "sell" rating to a "hold" rating in a research report on Saturday, February 14th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Carlsmed presently has a consensus rating of "Hold" and an average target price of $20.33. **Get Our Latest Stock Analysis on Carlsmed** ## Carlsmed Stock Down 2.8% CARL traded down $0.28 during trading on Thursday, reaching $9.71. The company had a trading volume of 15,227 shares, compared to its average volume of 119,126. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.87 and a quick ratio of 8.74. Carlsmed has a 12 month low of $8.86 and a 12 month high of $17.19. The business's fifty day moving average price is $11.45 and its 200 day moving average price is $12.66. The company has a market cap of $259.44 million and a P/E ratio of -2.68. Carlsmed (NASDAQ:CARL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.11. Carlsmed had a negative net margin of 58.67% and a negative return on equity of 72.60%. The firm had revenue of $15.16 million for the quarter, compared to analyst estimates of $15.20 million. ## Institutional Inflows and Outflows Hedge funds have recently bought and sold shares of the stock. Janney Montgomery Scott LLC increased its position in Carlsmed by 6.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 15,800 shares of the company's stock worth $195,000 after buying an additional 1,000 shares during the last quarter. Barclays PLC increased its position in Carlsmed by 10.6% during the fourth quarter. Barclays PLC now owns 10,633 shares of the company's stock worth $131,000 after buying an additional 1,021 shares during the last quarter. Russell Investments Group Ltd. increased its position in Carlsmed by 0.8% during the fourth quarter. Russell Investments Group Ltd. now owns 160,238 shares of the company's stock worth $1,979,000 after buying an additional 1,292 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Carlsmed during the third quarter worth approximately $33,000. Finally, JPMorgan Chase & Co. acquired a new position in Carlsmed during the third quarter worth approximately $37,000. ## Carlsmed Company Profile (Get Free Report) We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”). ## Recommended Stories - Five stocks we like better than Carlsmed *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Carlsmed Right Now? Before you consider Carlsmed, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Carlsmed wasn't on the list. While Carlsmed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [CARL.US](https://longbridge.com/en/quote/CARL.US.md) ## Related News & Research - [CMS finalizes new Medicare DRG reimbursement codes for Carlsmed aprevo lumbar fusion procedures](https://longbridge.com/en/news/294692142.md) - [Does Interparfums’ (IPAR) Earnings Upgrade Hint At Deeper Strength In Its Profit Model?](https://longbridge.com/en/news/296564505.md) - [Is Wall Street Bullish or Bearish on Cummins Stock?](https://longbridge.com/en/news/296615233.md) - [CONMED (CNMD) Could Be 8% Overvalued Following Its Recent Rebound](https://longbridge.com/en/news/296318744.md) - [Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales](https://longbridge.com/en/news/296529363.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**